Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling

Rearden, Rory, Sah, Amelia, Doff, Brianna, Kobayashi, Takumi, McKee, Sara J., Leggatt, Graham R. and Mattarollo, Stephen R. (2016) Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling. Immunology and Cell Biology, 94 6: 554-562. doi:10.1038/icb.2016.9


Author Rearden, Rory
Sah, Amelia
Doff, Brianna
Kobayashi, Takumi
McKee, Sara J.
Leggatt, Graham R.
Mattarollo, Stephen R.
Title Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling
Journal name Immunology and Cell Biology   Check publisher's open access policy
ISSN 1440-1711
0818-9641
Publication date 2016-02-09
Sub-type Article (original research)
DOI 10.1038/icb.2016.9
Open Access Status Not Open Access
Volume 94
Issue 6
Start page 554
End page 562
Total pages 9
Place of publication London, United Kingdom
Publisher Nature Publishing
Collection year 2017
Language eng
Formatted abstract
Immunomodulatory therapies can effectively control haematological malignancies by promoting antitumour immunity. Previously, we reported transient growth of poorly immunogenic murine non-Hodgkin B-cell lymphomas (B-NHL) by  targeting natural killer T (NKT) cells with a therapeutic vaccine approach. Therapeutic efficacy was highly dependent on the ability of the vaccine to provoke rapid interferon-gamma (IFNγ) production from NKT and NK cells. By manipulating the capacity of either host or lymphoma cells to signal through the IFNγ receptor (IFNγR), we investigated whether the therapeutic effect conferred by vaccine-induced IFNγ is a result of immune cell activation, lymphoma IFNγ sensitivity or a combination of both. We demonstrated that antitumour immunity elicited by vaccination requires IFNγ signalling within host cells but not tumour cells. IFNγR-deficient mice failed to mount an effective antitumour immune response following vaccination despite elevated IFNγ levels. With successive exposure to vaccination, lymphomas acquired an increasingly therapy-resistant phenotype and displayed a reduction in major histocompatibility complex I and CD1d surface expression, which is independent of tumour intrinsic IFNγ signalling. Our results suggest that immunotherapy-induced IFNγ production mainly exerts its therapeutic effect via signalling through host cells, rather than directly to tumour cells in B-NHL. This signifies that intact IFNγ signalling within patients’ immune compartment rather than tumour cell sensitivity to IFNγ is more critical for successful treatment. Finally, tumour IFNγ signalling alone does not drive acquired tumour resistance to vaccination, implying that additional immunoediting pathways are responsible for tumour immune escape.

Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 10 Feb 2016, 12:48:10 EST by Dr Graham Leggatt on behalf of UQ Diamantina Institute